Nov 24, 2020 7:30 am EST Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
Nov 12, 2020 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Nov 09, 2020 9:15 am EST Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
Nov 05, 2020 9:00 am EST Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
Sep 23, 2020 9:25 am EDT Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
Sep 10, 2020 9:15 am EDT Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Aug 25, 2020 9:15 am EDT Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
Aug 06, 2020 4:01 pm EDT Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 30, 2020 9:15 am EDT Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6